MD Anderson Cancer Network
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
June, 2024
June 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« May
MD Anderson Cancer Network
Jun 16, 2024, 05:49 |
Drugs
Vivek Subbiah: Another Tissue-Agnostic FDA approval
Vivek Subbiah shared on LinkedIn: . "Yes!…
Jun 15, 2024, 14:10 |
Drugs
Vivek Subbiah: FDA granted full traditional approval of RET inhibitor Selpercatinib in RET+ thyroid cancers
Vivek Subbiah shared on LinkedIn: . "FDA granted full traditional…
May 24, 2024, 00:42 |
Societies
Vivek Subbiah wholeheartedly supports and endorses Dr. Giuseppe Curigliano for ESMO President 2027-28
Vivek Subbiah shared on X: "Exciting news! The elections for the ESMO President 2027-2028 are…
Apr 8, 2024, 03:45 |
Drugs
Vivek Subbiah: First ADC tissue agnostic drug approved!
Quoting Vivek Subbiah's post on LinkedIn: "Just in time for American Association for Cancer Research…
Mar 16, 2024, 15:39 |
Blog
Sarah Sammons: DPYD testing is required before our pharmacy will dispense capecitabine
Sarah Sammons, Breast Medical Oncologist at Dana-Farber’s Breast Oncology Center, shared a post by Vivek Subbiah…
Mar 8, 2024, 15:14 |
Blog
Vivek Subbiah: Harnessing the potential of basket trials
Vivek Subbiah recently shared a post on X/Twitter: "Revolutionizing cancer drug development: Harnessing the potential…
All:
6
Posts:
1 - 10
Career Journey to President and CEO - OncoInfluencers
New Paper Alert! Long-Term Benefits of Dabrafenib-Trametinib in Stage III Melanoma: 8-Year COMBI-AD Trial Results
We mourn the loss of our Ivy Elkins
FDA grants accelerated approval to adagrasib with cetuximab for KRAS G12C-mutated colorectal cancer
Rob Winn: Honored to receive the ASCO Allen Lichter Visionary Leader Award
Facebook
RSS Feed
Twitter
Linkedin
Youtube